secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0000950170-25-063969
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OnKure Q1 net loss $15.9M, cash $96.7M; PIKture-01 trial on track for H2 2025 data
--------------------------------------------------------------------------------

- Net loss of $15.9M ($1.19 per share) vs $9.5M in Q1 2024; R&D expense rose to $13.0M.
- Cash and cash equivalents of $96.7M expected to fund operations into Q4 2026.
- PIKture-01 Part A monotherapy enrollment closed; mature data expected H2 2025.
- Part B fulvestrant combo dose escalation nearing completion; initial data in H2 2025.
- Pan-mutant PI3Kα development candidate to be announced in Q2 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000095017025063969/0000950170-25-063969-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000095017025063969/okur-20250506.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-063969

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer